- Completed
NCT01568866: Phase 3 - Carfilzomib and Dex Vs Bortezomib & Dex for Relapsed Myeloma (ENDEAVOR)
Updated: Jun 13, 2022
The ENDEAVOR Trial
KD Vs Vd
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR)
Sponsor
Amgen
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT01568866
Official Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
First Posted : April 2, 2012
Publications:
Lancet Oncol. 2016 Jan;17
Int J Hematol. 2019 Oct
Blood Cancer J. 2016 Jan
Leuk Lymphoma. 2017 Oct
Lancet Oncol. 2017 Oct
Locations
United States, California
United States, Colorado
United States, Florida
United States, Georgia
United States, Indiana
United States, Maryland
United States, Michigan
United States, Missouri
United States, New Jersey
United States, New York
United States, North Carolina
United States, Ohio
United States, Pennsylvania
United States, South Carolina
United States, Tennessee
United States, Texas
United States, Utah
Canada, Alberta
Canada, British Columbia
Canada, New Brunswick
Canada, Nova Scotia
Canada, Ontario
Canada, Quebec
Australia, New South Wales
Australia, Queensland
Australia, South Australia
Australia, Victoria
Australia, Western Australia
New Zealand
Europe
United Kingdom
Austria
Belgium
Bulgaria
Czechia
France
Germany
Greece
Hungary
Poland
Italy
Romania
Slovakia
Spain
Ukraine
Asia
Japan
Israel
Russian Federation
Korea, Republic of
Singapore
Taiwan
Thailand
South America
Brazil